According to DelveInsight, Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2017-2030 owing to the expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira) and other during the forecast period, i.e., 2020-2030.
DelveInsight’s “Atopic Dermatitis (AD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Atopic Dermatitis (AD), historical and forecasted epidemiology as well as the Atopic Dermatitis (AD) market trends in the 7MM.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
DelveInsight’s Atopic Dermatitis (AD) market report gives a thorough understanding of the Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.
Atopic dermatitis, also known as atopic eczema, is a condition that results in itchy, scaly and red skin. It is an inflammatory skin disease which is a common recurrent form of skin allergy. Acute flare-ups of eczematous pruritic lesions mainly categorise atopic dermatitis over dry skin due to high levels of immunoglobulin E (IgE).
Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide insights about historical and current Atopic Dermatitis (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
DelveInsight analysts revealed that total Atopic dermatitis prevalent population in 7MM was estimated to be around 41,261,411 in 2017.
Moreover, a higher Atopic dermatitis prevalence is observed in the United States approximately 19,460,609 cases, when compared with other geographies in 7MM, i.e., EU5 countries and Japan.
Atopic Dermatitis Market
Atopic dermatitis market analysis by DelveInsight revealed that the total market size in 7 MM was estimated to be around USD 2422 Million in 2017.
According to DelveInsight, Atopic Dermatitis (AD) market in 7MM is expected to change in the study period 2017-2030 owing to the expected launch of PF-04965842 (Pfizer), ZPL389 (Novartis Pharmaceuticals), DS-2741a (Daiichi Sankyo), Upadacitinib (AbbVie), PUR0110 (PurGenesis Technologies), Lebrikizumab (Dermira) and other during the forecast period, i.e., 2020–2030.
The Atopic Dermatitis (AD) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Atopic Dermatitis (AD) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Atopic Dermatitis (AD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
- In the coming years, Atopic Dermatitis (AD) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Atopic Dermatitis (AD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Atopic Dermatitis (AD). Launch of emerging therapies will significantly impact the Atopic Dermatitis (AD) market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Atopic Dermatitis (AD)
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Table of contents
- 1. Key Insights
- 2. Executive Summary of Atopic Dermatitis (AD)
- 3. Competitive Intelligence Analysis for Atopic Dermatitis (AD)
- 4. Atopic Dermatitis (AD): Market Overview at a Glance
- 5. Atopic Dermatitis (AD): Disease Background and Overview
- 6. Patient Journey
- 7. Atopic Dermatitis (AD) Epidemiology and Patient Population
- 8. Treatment Algorithm, Current Treatment, and Medical Practices
- 9. Unmet Needs
- 10. Key Endpoints of Atopic Dermatitis (AD) Treatment
- 11. Marketed Products
- 12. Emerging Therapies
- 13. Atopic Dermatitis (AD): Seven Major Market Analysis
- 14. Attribute analysis
- 15. 7MM: Market Outlook
- 16. Access and Reimbursement Overview of Atopic Dermatitis (AD)
- 17. KOL Views
- 18. Market Drivers
- 19. Market Barriers
- 20. Appendix
- 21. DelveInsight Capabilities
- 22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States